First-line combination immunotherapy for metastatic non-small cell lung cancer.

Journal of the Chinese Medical Association : JCMA
Yuh-Min Chen

Abstract

Immunotherapy has recently become an important treatment modality, especially for non-small cell lung cancer (NSCLC) and melanoma patients. Several large-scale phase III trials of first-line treatments for metastatic NSCLC have documented prolonged patient survival, including progression-free survival and overall survival for immune checkpoint inhibitors (ICIs) used alone or in combination with chemotherapy. However, a significant proportion of patients experienced disease progression shortly after starting single-agent ICI treatment even after biomarker selection, such as programmed cell death-ligand 1 and tumor mutation burden. The present review was performed to identify ways to enhance ICI efficacy in the first-line treatment of metastatic NSCLC patients. At least four effective ways of combination treatment modalities are currently available, namely, immune therapy in combination with radiotherapy, chemotherapy, antiangiogenesis, or other immunotherapeutic agents.

References

Dec 22, 2007·Nature Reviews. Immunology·Laurence ZitvogelGuido Kroemer
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jan 21, 2011·Cancer Metastasis Reviews·Oliver KeppGuido Kroemer
Feb 8, 2013·Cancer Immunology, Immunotherapy : CII·Gang Chen, Leisha A Emens
Jul 31, 2013·Immunity·Daniel S Chen, Ira Mellman
May 6, 2015·Cancer Immunology Research·Leisha A Emens, Gary Middleton
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jul 25, 2015·Nature Reviews. Cancer·Ignacio MeleroJohn Haanen
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Oct 4, 2016·Journal of the Chinese Medical Association : JCMA·Yuh-Min Chen
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 3, 2016·Cancer Immunology Research·Lorenzo GalluzziGuido Kroemer
Nov 3, 2016·The New England Journal of Medicine·Vassiliki A Boussiotis
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E LanitisG Coukos
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Feb 14, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason J LukeSteven J Chmura
Mar 7, 2018·Nature Reviews. Clinical Oncology·Dai FukumuraRakesh K Jain
Apr 17, 2018·The New England Journal of Medicine·Matthew D HellmannLuis Paz-Ares
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Sep 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tara C MitchellThomas F Gajewski
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Dec 12, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James Chih-Hsin YangAmita Patnaik
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer
Jan 16, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pablo MartinezJean-Charles Soria
Feb 15, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James Chih-Hsin YangLeora Horn
Feb 23, 2019·Translational Lung Cancer Research·Alexander J LinClifford Robinson
Mar 3, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Deborah B DoroshowRoy S Herbst
Mar 9, 2019·Cell·Rajendra S ApteNapoleone Ferrara
May 28, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MazieresO Gautschi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.